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Background: CD4 cell response in patients on second-line therapy has not been evaluated in Kenya. Patients failing 
second-line are changed to third-line, however, the drugs used for third-line are expensive and unavailable. Therefore, 
early identification of potential poor responders to treatment would lead to early intervention and thus improve 
therapy of patients on second-line.  
Objectives: To identify socio-demographic and treatment related variables that affect CD4 response of HIV-positive 
patients on second-line regimens in Kenyatta National Hospital (KNH). 
Methods: A historical cohort study carried out at KNH between January and April 2016 and entailed collection of 
patient data from the files. The main outcome variable was CD4 cell count.  The predictor variables of interest were 
sex, age, education level, and ART regimens.  
Results: All the study participants were on a lopinavir-based regimen. The study involved 84 study participants, 
59.5% female study participants and 40.5% male. Male patients had significantly lower baseline CD4 cell counts and 
lower CD4 cell counts at ART (antiretroviral therapy) switch to second line compared to female patients. Efavirenz-
based regimens were significantly associated with low CD4 cell count at ART switch to second-line.  
Conclusion: Patients should be started on nevirapine-based regimens unless contraindicated. 
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1. Introduction 
In sub-Saharan Africa, 24.7 million people were living 
with HIV in 2013 and there were 1.2 million AIDS-
related deaths in 2012 (UNAIDS, 2013).  In Kenya, 1.6 
million people were estimated to be living with HIV in 
2013 and 1.5 million in 2015.  The HIV prevalence in 
Kenya among people aged 15-49 was 6% in 2013 and 
5.9% in 2015.  Prevalence was higher in women 
compared to men; in women the prevalence was 7.6% 
while in men it was 5.6% (NASCOP, 2014b). 
The Kenyan Guidelines on Management of HIV in 2016 
recommend that all individuals with confirmed HIV 
infection are eligible for ART provided that they are 
willing and ready to take and adhere to ART. Patients on 
ART are routinely followed up.  CD4 cell count 
determination is done during initiation and every six 
months especially where viral load testing is not 
available.  Viral load determination is done after 6 and 
12 months of initiating therapy and thereafter annually 
(NASCOP, 2014).  According to the Kenya ART 
Guidelines 2016, patients who experienced treatment 
failure were to be changed to second line regimen.   
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The recommended second-line ART regimens for adults 
are tenofovir (TDF) or zidovudine (AZT) + lamivudine 
(3TC) + atazanavir/ritonavir (ATV/r) or 
lopinavir/ritonavir (LPV/r). In cases of second-line ART 
regimen failure, the options for third-line are limited 
but include integrase inhibitors like raltegravir, new-
generation NNRTIs like etravirine, protease inhibitors 
like darunavir and recycling of drugs that confer benefit 
like lamivudine and tenofovir (NASCOP, 2011). 
Initiation of third line regimen is based on HIV drug 
resistance patterns (NASCOP, 2014a). 
Adherence to ART is critical in determining the 
immunological response.  Patients who adhere to ART 
are more likely to have higher CD4 cell count compared 
to those who do not (Abrogoua et al., 2012). In a study 
done in Ethiopia, advanced clinical stage, anemia, low 
body weight, and lack of co-trimoxazole prophylaxis 
were predictors of mortality in HIV patients.  In the 
same study, sex was not a predictor of mortality (Alemu 
and Sebastián, 2010).   
Another study in Ethiopia indicated that WHO Stage 
III/IV of HIV disease or a higher CD4 cell count at 
baseline were risks for immunological failure (Yirdaw 
and Hattingh, 2015). In a study in South Africa, 
variables that significantly affected immunological 
response were older age and CD4 cell count at initiation 
of ART while body mass index, baseline haemoglobin, 
sex, concurrent TB co-infection and ART regimen did 
not affect immunological response significantly (Julg et 
al., 2012).  A study in Ethiopia concluded that low 
baseline CD4 cell count, old age and higher educational 
status were associated with reduced CD4 cell count 
leading to immunological treatment failure (Teshome 
and Assefa, 2014). A study done in Western Kenya also 
found out that baseline CD4 cell count, age and use of 
stavudine were important predictors at change to 
second-line therapy (Inzaule et al., 2014). 
Nutritional supplements taken with ART improve 
immune response in HIV –positive patients (Evans et al., 
2013).  Alcohol abuse leads to lower CD4 cell counts 
(Iralu et al., 2010).  Patient’s age, smoking, use of illicit 
drugs, hospital treatment, changing doctors and the use 
of ART affects the CD4 cell count (Montarroyos et al., 
2014).  Low CD4 cell counts were associated with high 
incidence of anaemia, lymphopenia and 
thrombocytopenia (Parinitha and Kulkarni, 2012).    
Psychosocial variables like depression and singlehood 
can affect adherence and hence affect CD4 cell count 
and eventually treatment response (Langford et al., 
2007).  Genetic variables may also affect immunological 
response(Coloccini et al., 2014; Zhu et al., 2013). 
CD4 cell count is a key indicator of HIV disease 
progression (Langford et al., 2007). Patients with a low 
CD4 cell count normally have a greater risk of diseases 
(Pinzone, Di Rosa, Cacopardo, and Nunnari, 2012). CD4 
cell response is also important in monitoring the 
success of antiretroviral therapy (Montarroyos et al., 
2014). Low CD4 cell count is associated with mortality 
in patients on ART (Odafe et al., 2012). Therefore, CD4 
cell count is a key predictor of treatment failure. 
CD4 cell response in patients on second-line therapy 
has not been evaluated in Kenya. This study sought to 
identify socio-demographic and treatment related 
variables that affect CD4 response of HIV-positive 
patients on lopinavir-based regimens in Kenyatta 
National Hospital. It is hoped that identification of these 
variables will lead to early identification of potential 
poor responders to treatment leading to early 
intervention to improve therapy. 
2. Methods 
2.1 Study design, site and population 
The design was a retrospective cohort study and 
entailed collection of patient data recorded in patient 
files from the time of initiation of therapy. The study 
was conducted at the Comprehensive Care Centre (CCC) 
of the Kenyatta National Hospital, which is the largest 
teaching and referral hospital in Kenya and East and 
Central Africa, with a diverse inter-ethnic population of 
patients. The study population consisted of HIV patients 
on any lopinavir-based second-line ART regimen who 
were seen at the KNH CCC between January 2016 and 
April 2016. 
2.2 Inclusion and Exclusion criteria 
The patients included in the study were HIV infected 
patients on any lopinavir-based second-line ART, at 
least 6 months of second-line ART, aged above 18 years, 
of either sex and gave informed consent to participate 
in the study. The patients excluded from the study were 
those who declined to give consent, were on second-line 
ART for less than 6 months and aged below 18 years. 
2.3 Sample size  
The expected main outcome of interest is change of CD4 
levels. Consequently the Twisk (2003) formula for 
estimation of sample size of a continuous outcome 
variable in a cohort study was used.  
The sample size needed to make a 0.3 difference in a 
continuous outcome variable statistically significant on 
a 5% level with a power of 80% with different within-
subject association coefficients (ρ) of 0.5 and four 
repeated measurements was 59.  To accommodate for 
expected missing files or incomplete data entries, the 
calculated sample size was inflated by 20%.  Therefore, 
a minimum sample size of 71 participants was targeted. 
2.4 Data collection 
Data was abstracted from the patient files using a data 
collection tool. Demographic data collected included 
sex, age, body mass index, marital status, occupation, 
education and ethnicity. Clinical data collected included 
first line ART regimen and duration, second line ART 
regimen and duration, WHO staging, CD4 cell count at 
different time points, viral load, adherence, 
haemoglobin, ALT (Alanine transaminase) and 
creatinine levels. 
2.5 Variables and outcomes 
The main outcome variable in this study was CD4 cell 
count.  The predictor variables of interest were sex, 
ethnicity, age, education level, ART regimens, body mass 
index and duration of therapy. 
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2.6 Data analysis 
All variables were subjected to descriptive data 
analysis. Shapiro-Wilk test was used to determine if the 
continuous variables were normally distributed. Mean 
and standard deviation were used to summarize 
variables that were normally distributed and those that 
were not normally distributed were expressed as the 
median and inter- quartile range.   
Multi-linear regression was then conducted to identify 
variables associated with baseline CD4 count (CD4 cell 
count at initiation of ART), CD4 count at ART switch 
from first-line to second-line and CD4 cell count at 
recruitment to the study. Generalized linear modelling 
with adjustment for clustering within the patients was 
done to identify the variables associated with rate of 
change of CD4 cell count. Manual forward stepwise 
model building was then done in all regression analyses. 
Data analysis was conducted using STATA version 10 
software. The level of significance was set at 0.05. 
2.7 Ethical considerations 
Permission to conduct the study was granted by the 
KNH/UoN Research and Ethics committee (Ref: KNH-
ERC/A/499). The letter that granted ethical approval is 
attached in Appendix C. The nature of the study was 
fully disclosed to the participants. Patients provided 
informed consent to participate in the study and data 
collected was handled with confidentiality  
 
     Table 1: Baseline socio-demographic and clinical characteristics  
Variables n (%) or Median [IQR] 
Sex  
Male 34 (40.5) 
Female 50 (59.5) 
Age At diagnosis in years 36 [32 – 44] 
Weight at diagnosis (kg) 61 [54.2 – 71.2] 
Height at diagnosis (cm) 165 [158 – 171] 
BMI at HAART initiation  
< 18.5 5 (6.0) 
18.5 - 24.9 34 (40.5) 
> 24.9 18 (21.4) 
Missing values 27 (32.1) 
Ethnolinguistic Groups  
Bantu 53 (63.1) 
Nilotes 30 (35.7) 
Cushites 1 (1.2) 
Education level  
Primary level and below 13 (19.7) 
Secondary level 37 (56.1) 
Above tertiary level 16 (24.2) 
Regimens at initiation of HAART 
TDF + 3TC + NVP   19 (22.6) 
AZT + 3TC + NVP   11 (13.1) 
AZT + 3TC + EFV   20 (23.8) 
d4T + 3TC + NVP   15 (17.9) 
d4T + 3TC + EFV   8 (9.5) 
TDF + 3TC + EFV   9 (10.7) 
d4T + DDI + EFV 2 (2.4) 
First-line Duration of therapy 2 [0 – 5] 
Second-line Duration of therapy 4 [2 – 6] 
ALT at HAART initiation 23 [16 – 44] 
Normal (≤ 40U/L) 22 (26.2) 
Elevated (> 40U/L) 11 (13.1) 
Missing values 51 (60.7) 
Creatinine Levels 79. 5 [64.5 – 93] 
Normal (≤ 120µmol/l) 32 (38.1) 
Elevated (>120µmol/l) 4 (4.8) 
Missing values 48 (57.1) 
CD4 Cell Counts X 109L at diagnosis 88 [19 – 284] 
≤ 200 49 (58.3) 
> 200 19 (22.6) 
Missing values 16 (19.1) 
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3. Results  
All the study participants were on a lopinavir-based 
regimen. The study involved 84 study participants, 52 
(61.9%) were on TDF + 3TC + Lopinavir/ritonavir 
(LPV/r) while 25 (29.8%) were on AZT + 3TC + LPV/r 
and 7 (8.3%) were on Abacavir (ABC) + 3TC + LPV/r. 
They were on second-line antiretroviral therapy since 
they had experienced either immunological failure or 
virological failure on first line therapy. The first line 
regimens that the study participants had previously 
used are presented in Table 1. 
There were 50 (59.5) female study participants and 34 
(40.5) male. The median age was 36 years [interquartile 
range (IQR) 32 – 44]. The median baseline body weight 
was 61 [IQR 54.2 – 71.2]. There were 5 (6.0%) patients 
with a baseline body mass index (BMI) of less than 18.5 
while 34 (40.5%) had normal BMI. Only 16 (24.2%) 
study participants had tertiary education and above.  
The median of duration of therapy during first line ART 
treatment was 2 years [IQR 0 – 5] while that during 
second line was 4years [IQR 2 – 6]. The median 
creatinine levels at HAART initiation was 79. 5 [IQR 
64.5 – 93] while the median ALT levels was 23 [IQR 16 – 
44]. A summary of the baseline characteristics is 
presented in Table 1. 
Longitudinal changes of CD4 cell counts  
The baseline, CD4 cell counts at switch and at 
recruitment are presented in Table 2. The median CD4 
cell counts increased from baseline to treatment switch 
and at recruitment. At all three time points, younger 
patients below 40 years and females had higher median 
CD4 cell counts compared to their counterparts. 
Patients who had been on TDF+3TC+EFV had the lowest 
median CD4 cell counts at ART switch while those on 
AZT+3TC+NVP and D4T+3TC+NVP had the highest 
median CD4 cell counts. Study participants on AZT + 
3TC + LPV/r had the highest CD4 cell counts at 
recruitment followed by those on TDF + 3TC +LPV/r. 
The participants on ABC + 3TC + LPV/r had the lowest 
CD4 cell counts at recruitment. 
 
Table 2: CD4 cell counts at Baseline, ART switch and at recruitment attained in the study population 
Patient Characteristics 
Baseline CD4 cell 
counts, median [IQR] 
CD4 cell counts at ART 
switch, median [IQR] 
Current CD4 levels 
attained, median [IQR] 
Sex    
Male 57.5 [15 – 254] 173.5 [56 – 294.5] 340 [221-441] 
Female 131 [33-445.5] 374 [179.5-491] 554 [334-722] 
Age    
≤ 40 115 [30-288] 303 [173-473] 437 [485-608] 
> 40 88 [11-254] 189.5 [85-414] 358 [244-619.5] 
BMI at initiation    
Underweight(< 18.5) 4 [2-132]  340 [296-374] 
Elevated (18.5 - 24.9) 69 [19-288]  470 [309-617] 
Overweight or Obese (> 24.9) 94 [30-180]  419.5 [164-514] 
First-line regimens    
  TDF+3TC+NVP - 329 [167.5-444] 366 [297-441] 
  AZT+3TC+NVP - 464 [313-606] 514 [346-781] 
  AZT+3TC+EFV - 134 [70-222] 689 [689-689] 
  D4T+3TC+NVP - 473.5 [197-706] 150 [32-245] 
  D4T+3TC+EFV - 270 [218-365] 597.5 [400-722] 
  TDF+3TC+EFV - 9 [6-42] 440.5 [374.5-655.5] 
  D4T+DDI+EFV - 254 [254-254] 420 [253.5-574] 
Current Regimens    
ABC + 3TC + LPV/r - - 243 [150-554] 
AZT + 3TC + LPV/r - - 497.5 [114.5-683.5] 
TDF + 3TC + LPV/r - - 414 [305-617] 
 
Variables associated with baseline CD4 cell counts 
In order to transform the CD4 cell counts to be normally 
distributed, the log baseline CD4 cell counts were 
generated. On univariable analysis, the variables 
associated with baseline CD4 cell counts were baseline 
creatinine and weight. On multivariable analysis, 
baseline creatinine (p<0.01) was the most important 
predictor for CD4 response at baseline and it remained 
significant even after adjusting for confounding by 
weight, body mass index, age, ALT, sex and WHO 
staging. Increased creatinine levels by one unit led to 
decreased baseline log CD4 levels by 0.004 units (-
0.006, -0.003). 
Variables associated with CD4 cell counts at ART 
switch to second line 
In order to transform the CD4 cell counts to be normally 
distributed, the square root of the CD4 cell counts were 
generated. When univariable analysis was done, the 
study participants with low baseline weight and lower 
education level were significantly associated with 
higher square root of CD4 cell count at ART switch. 
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Those on efavirenz-based regimens had lower square 
root of CD4 count at ART switch compared to those on 
nevirapine-based regimens. Female study participants 
had higher square root of CD4 cell counts compared to 
the male study participants.  
On adjusting for confounding, TDF+3TC+EFV (p<0.01), 
sex (p<0.03), weight (p<0.05) and baseline CD4 cell 
count (p<0.02) had a significant association with square 
root of CD4 cell counts at ART switch to second-line. 
Patients who had been on TDF+3TC+EFV had lower 
square root of CD4 cell count compared to other 
regimens by 8.887 units. An increase of weight by one 
kilogram resulted to a decrease of square root of CD4 
cell count by 0.145 units. On the other hand, an increase 
in baseline CD4 cell count by one unit led to an increase 
in square root of CD4 cell count at change of therapy by 
0.012 units. Females had a significantly higher square 
root of CD4 cell count at ART switch compared to males 
by 4.201 units. 
Variables associated with rate of change of the CD4 
cell counts 
The logarithm of the CD4 cell counts was obtained and 
regressed against covariates using generalized linear 
modelling. On univariate analysis, the variables that 
were significant were sex, education level above 
tertiary, baseline creatinine, CD4 count at ART switch 
and first-line regimen. On multivariable analysis, sex 
(p<0.01), education level above tertiary (p<0.01), 
TDF+3TC+EFV (p<0.01) and an interaction between 
duration and education level still had a significant 
association with rate of change of CD4 cell count 
(p<0.01). 
In order to improve the interpretation of the findings of 
generalized linear regression analysis, predictive plots 
were generated for each of the variables that were 
significant.  
Effect of Education on rate of change of CD4 cell count 
From generalized linear modelling, education affected 
the rate of change because the interaction between 
duration and education above tertiary level was 
statistically significant. The study participants who had 
tertiary education had lower CD4 cell counts at time of 
treatment switch but a higher rate of change of log CD4 
cell counts while the study participants who did not 
have tertiary education had a higher CD4 cell counts at 
ART switch but a lower rate of change of log CD4 cell 
counts. This is illustrated in Figure 1. 
Effect of Sex on rate of change of CD4 cell count 
Females had consistently higher log CD4 cell counts 
compared to males. However, males had a slightly 
higher rate of change of log CD4 cell count compared to 
females as illustrated in Figure 2. 
Effect of first-line regimen on rate of change of CD4 cell 
count 
In order to control for the effect of education, two 
different plots of the rate of change of CD4 cell counts vs 
first line regimen were generated; the first for 
participants without tertiary education and the second 
for those with tertiary education. Patients who had been 
on TDF+3TC+EFV had consistently lower CD4 cell 
counts after ART switch than those who had been on 
other regimens. However, they had a higher rate of 
change of CD4 compared to those who had been on 
other regimens as illustrated in Figure 3. 
 
Figure 1: Effect of education on rate of change of CD4 
cell count 
 
Figure 2: Effect of Sex on rate of change of CD4 cell 
count 
 
Variables associated with CD4 cell counts at 
recruitment to the study 
In order to transform the CD4 cell counts to be normally 
distributed, the square root of CD4 cell counts were 
generated. Square root of CD4 cell count at recruitment 
to the study was computed and regressed against 
various covariates. On univariate analysis, higher 
baseline weight, higher baseline creatinine levels, those 
with high education level and those on ABC+3TC+LPV/r 
were significantly associated with lower square root of 
CD4 cell counts at recruitment. Low CD4 cell counts at 
ART switch and low baseline WHO stage were 
significantly associated with low square roots of CD4 
cell counts at recruitment. Females had a higher CD4 
cell count at recruitment to the study compared to 
males.  
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On multivariable analysis, CD4 cell count at ART switch 
(p<0.05), education level (p<0.03) and baseline WHO 
stage (p<0.03) were important predictors of CD4 cell 
counts at recruitment. Participants with higher 
education level had lower CD4 cell count at recruitment 
while those who had a higher CD4 cell count at ART 
switch to second-line had a higher CD4 cell count at 
recruitment to the study. In addition, participants with a 
higher WHO stage at initiation of ART had a higher CD4 
cell count at recruitment. 
 
  
Figure 3: Difference in the rate of change in log CD4 counts of patients on TDF+3TC+EFV and other regimens 
4.0 Discussion 
Male study participants had lower baseline CD4 cell 
counts compared to female study participants. 
However, this was not statistically significant. A study 
done among Kenyan study participants found out that 
males had lower baseline CD4 cell counts and this was 
statistically significant, probably because the study had 
a larger sample size (Angima, 2015). 
Female study participants had higher CD4 cell counts 
compared to male study participants at change to 
second-line antiretroviral therapy. A study done in 
Nigeria reported that males were more likely to be 
associated with loss to follow up (Odafe et al., 2012). 
This suggests that males are more likely to have poor 
adherence and this may lead to decline in CD4 cell 
response. Another study done in Burkina Faso indicated 
that men were strongly associated with virologic failure 
probably due to poor adherence (Penot et al., 2014). 
These studies were an indication that men were more 
likely to have poor adherence and this could explain 
their low CD4 cell count at ART switch.  
Efavirenz-based regimens especially TDF+3TC+EFV 
were significantly associated with low CD4 cell count at 
ART switch compared to nevirapine-based regimens. 
Patients who had been on TDF+3TC+EFV still had 
significantly lower CD4 cell counts compared to those 
who had been on other regimens even after change of 
therapy from first-line to second-line. However, a study 
done in Uganda indicated that nevirapine was more 
likely to be associated with treatment failure than 
efavirenz (Sebunya et al., 2013). These findings suggest 
that current treatment guidelines need to be critically 
reviewed with regard to selection of NVP viz a viz EFV 
based regimens.  The available scientific literature on 
the comparative effectiveness of these agents needs to 
be critically reviewed so as to guide treatment selection. 
There was no statistically significant association 
between the second-line ART regimens and the Cd4 cell 
count at recruitment to the study in this study. This was 
in agreement with a study done in Ghana which did not 
find any significant association between CD4 cell count 
and type of ART regimen (Barry et al., 2013). 
Baseline CD4 cell count significantly affected CD4 cell 
count at ART switch in this study. This was in 
agreement with a study done in Western Kenya which 
also found out that baseline CD4 cell count was an 
important predictor at change of therapy to second-line 
therapy (Inzaule et al., 2014). Another study done in 
South Africa also found out that baseline CD4 cell counts 
were determinants for recovery (Julg et al., 2012). A 
study in Ethiopia concluded that low baseline CD4 cell 
count was associated with immunological failure hence 
reduced CD4 cell count at ART switch (Teshome and 
Assefa, 2014). 
Study participants with tertiary education and above 
had consistently lower CD4 cell counts than those 
without tertiary education. This is probably because 
they went to the hospital late as they tried to self-
medicate or they were more likely to be in denial of 
their HIV status. A study in Ethiopia concluded that 
higher education was associated with reduced CD4 cell 
count leading to immunological treatment failure 
(Teshome and Assefa, 2014). However, study 
participants with tertiary education and above had a 
higher rate of change of CD4 cell count after ART switch 
compared to those without tertiary education. This is 
probably because they were more likely to understand 
the impact of treatment failure and hence they would 
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have improved adherence. This would have led to a 
higher rate of change of CD4 cell count. 
In this study, there was no significant association 
between age and CD4 cell response. This is probably 
because this cohort was of patients who had already 
failed first-line regimen and thus younger patients were 
more likely to have still been using first-line regimens. 
This was unlike a study done in South Africa which 
reported a significant association between old age and 
severe CD4 cell count decline (Julg et al., 2012). A study 
in Ethiopia concluded that old age was associated with 
reduced CD4 cell count leading to immunological 
treatment failure (Teshome and Assefa, 2014). Other 
studies have also shown an association between age 
and rate of change of CD4 cell count (Montarroyos et al., 
2014). 
5.0 Conclusion  
Male patients had significantly lower CD4 cell counts at 
baseline and at ART switch compared to female 
patients. Patients who had been on efavirenz-based 
regimens especially TDF+3TC+EFV were significantly 
associated with low CD4 cell count at ART switch 
compared to nevirapine-based regimens. In addition, 
Study participants with tertiary education and above 
had consistently lower CD4 cell counts compared to 
those without tertiary education. However, they had a 
higher rate of change of CD4 cell count after ART switch 
compared to those without tertiary education. 
Patients should be started on nevirapine-based 
regimens unless contraindicated since participants on 
efavirenz-based regimens had systematically lower CD4 
cell counts even after switching therapy to second-line. 
However, larger studies need to be done to compare the 
effectiveness of these two drugs. In addition, effort 
should be made to improve adherence among male 
patients. 
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